<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Access J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Open Access J Urol</journal-id><journal-title-group><journal-title>Open Access Journal of Urology</journal-title></journal-title-group><issn pub-type="epub">1179-1551</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24198629</article-id><article-id pub-id-type="pmc">3818930</article-id><article-id pub-id-type="doi">10.2147/OAJU.S15333</article-id><article-id pub-id-type="publisher-id">oaju-3-001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gittelman</surname><given-names>Marc C</given-names></name><xref ref-type="aff" rid="af1-oaju-3-001">1</xref><xref ref-type="corresp" rid="c1-oaju-3-001"/></contrib><contrib contrib-type="author"><name><surname>Marks</surname><given-names>Leonard S</given-names></name><xref ref-type="aff" rid="af2-oaju-3-001">2</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Lawrence A</given-names></name><xref ref-type="aff" rid="af3-oaju-3-001">3</xref></contrib><contrib contrib-type="author"><name><surname>Volinn</surname><given-names>Weining</given-names></name><xref ref-type="aff" rid="af3-oaju-3-001">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoel</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="af3-oaju-3-001">3</xref></contrib></contrib-group><aff id="af1-oaju-3-001"><label>1</label>South Florida Medical Research, Aventura, Florida, USA</aff><aff id="af2-oaju-3-001"><label>2</label>University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California, USA</aff><aff id="af3-oaju-3-001"><label>3</label>Watson Laboratories, Salt Lake City, Utah, USA</aff><author-notes><corresp id="c1-oaju-3-001">Correspondence: Marc Gittelman, South Florida Medical Research, 21st Century Oncology/UroMedix-Aventura Division, 21150 Biscayne Boulevard, Suite 300, Aventura, FL 33180, USA Tel +1 305-931-8080 Fax +1 305-931-7024 Email <email>mgittelman@southfloridamedicalresearch.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2010</year></pub-date><volume>3</volume><fpage>1</fpage><lpage>5</lpage><permissions><copyright-statement>&#x000a9; 2011 Gittelman et al, publisher and licensee Dove Medical Press Ltd</copyright-statement><copyright-year>2011</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective &#x003b1;-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). This analysis evaluated the effect of silodosin on each symptom assessed by IPSS questionnaire.</p></sec><sec><title>Materials and methods</title><p>Study participants (N = 923) were men aged &#x02265;50 years with IPSS &#x02265;13 and Qmax 4&#x02013;15 mL/s. They received silodosin 8 mg or placebo once daily for 12 weeks. Patient responses to 7 IPSS questions were collected at weeks 0 (baseline), 0.5, 1, 2, 4, and 12 and scored on a 6-point scale. Efficacy of silodosin versus placebo was assessed by analysis of covariance.</p></sec><sec><title>Results</title><p>For each symptom, the 2 treatment groups had similar mean baseline scores. Decrease in score from baseline (mean &#x000b1; standard deviation) to last observation was significantly greater with silodosin than with placebo for all symptoms (<italic>P</italic> &#x0003c; 0.005); symptom improvement with silodosin (versus placebo) was greatest for weak stream (silodosin, &#x02212;1.1 &#x000b1; 1.4 versus placebo, &#x02212;0.5 &#x000b1; 1.2; <italic>P</italic> &#x0003c; 0.0001) and smallest for nocturia (silodosin, &#x02212;0.6 &#x000b1; 1.1 versus placebo, &#x02212;0.4 &#x000b1; 1.2; <italic>P</italic> = 0.0037). Compared with placebo, silodosin significantly improved nocturia within 1 week (silodosin, &#x02212;0.5 &#x000b1; 1.07 versus placebo, &#x02212;0.3 &#x000b1; 1.05; <italic>P</italic> = 0.009) and all other symptoms within 3 to 4 days (<italic>P</italic> &#x0003c; 0.01).</p></sec><sec><title>Conclusions</title><p>Silodosin significantly improved all BPH-associated symptoms assessed by IPSS questionnaire within the first week of treatment. All improvements were maintained over the 12-week study period.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>BPH</kwd><kwd>symptoms</kwd><kwd>rapid onset</kwd><kwd>silodosin</kwd><kwd>&#x003b1;<sub>1A</sub>-adrenoceptor antagonist</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Benign prostatic hyperplasia (BPH) is a chronic condition often associated with lower urinary tract symptoms (LUTS). The severity of BPH-related LUTS appears to depend at least in part, on smooth muscle tone in the prostate and bladder neck, which is mediated by &#x003b1;<sub>1A</sub> -adrenoceptors.<xref ref-type="bibr" rid="b1-oaju-3-001">1</xref>,<xref ref-type="bibr" rid="b2-oaju-3-001">2</xref> &#x003b1;-Blockers (&#x003b1;<sub>1</sub>-adrenoceptor antagonists) have become the therapy of choice for patients with BPH-related LUTS because they provide effective symptom relief, are generally well tolerated and are relatively inexpensive.<xref ref-type="bibr" rid="b3-oaju-3-001">3</xref> However, &#x003b1;-blockers vary in their propensity to cause blood pressure-related adverse events, which have been attributed to the blockade of &#x003b1;<sub>1B</sub> -adrenoceptors in arterial vessels.<xref ref-type="bibr" rid="b2-oaju-3-001">2</xref>,<xref ref-type="bibr" rid="b4-oaju-3-001">4</xref>,<xref ref-type="bibr" rid="b5-oaju-3-001">5</xref></p><p>Silodosin is an &#x003b1;-blocker that recently has been approved in the United States (US) for treatment of the signs and symptoms of BPH. The pharmacological properties of silodosin are characterized by an exceptionally high selectivity for the &#x003b1;<sub>1A</sub>- versus &#x003b1;<sub>1B</sub>-adrenoceptor subtype.<xref ref-type="bibr" rid="b6-oaju-3-001">6</xref>,<xref ref-type="bibr" rid="b7-oaju-3-001">7</xref> Moreover, silodosin has been shown to be highly selective for prostatic versus vascular tissue.<xref ref-type="bibr" rid="b8-oaju-3-001">8</xref>&#x02013;<xref ref-type="bibr" rid="b10-oaju-3-001">10</xref> Consistent with this observation, results from phase III clinical studies suggest that silodosin carries minimal risk for orthostatic hypotension and overall has excellent cardiovascular tolerability.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref>,<xref ref-type="bibr" rid="b12-oaju-3-001">12</xref></p><p>Combined efficacy results from the phase III clinical studies showed that silodosin can promote rapid and significant improvement in BPH-associated urinary symptoms and peak urinary flow rate and can substantially improve LUTS-related quality of life.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> Overall symptom improvement was evaluated on the basis of aggregate patient scores for 7 distinct symptoms addressed by the International Prostate Symptom Score (IPSS) questionnaire. This post hoc analysis determined the effect of silodosin on each of the 7 symptoms.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="methods|subjects"><title>Patients and study design</title><p>This post hoc analysis of combined data from two 12-week randomized, double-blind, placebo-controlled US studies (NCT00224107, NCT00224120, at <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>) evaluated the efficacy and safety of silodosin for the treatment of signs and symptoms of BPH. The study has been described in detail and overall results published.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> Briefly, study participants were at least 50 years of age with an IPSS greater than 13, a peak urinary flow rate (Qmax) of 4 to 15 mL/s, and a postvoid residual volume less than 250 mL. Patients first received single-blind treatment with placebo for 4 weeks. Those with at least a 30% decrease in IPSS or an increase in Qmax of 3 mL/s or greater during the placebo run-in period were excluded from randomization. Eligible patients were randomly assigned (1:1) to doubleblind treatment with placebo or silodosin 8 mg once daily with breakfast for 12 weeks. The primary end point was the change in IPSS from baseline to the last observation. IPSS was assessed during clinical visits at weeks 0 (baseline), 1, 2, 4, and 12 and by phone interview on day 3 or 4 of the first week (week 0.5).</p></sec><sec sec-type="methods"><title>Analysis</title><p>This post hoc analysis evaluated changes in individual symptom scores as assessed by IPSS questions. All randomized study participants (N = 923) who provided baseline data for the primary efficacy variable (total IPSS) were included in the analysis; 466 patients received silodosin and 457 received placebo.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> The IPSS questionnaire assesses 7 distinct urinary symptoms. Frequency (question [Q2]), urgency (Q4), and nocturia (Q7) are classified as irritative symptoms. Incomplete emptying (Q1), intermittency (Q3), weak stream (Q5), and straining (Q6) are classified as obstructive symptoms. Severity of each symptom is scored on a 6-point scale.<xref ref-type="bibr" rid="b13-oaju-3-001">13</xref></p><p>Mean changes in score from baseline with 95% confidence intervals (CIs) were calculated for observed cases at each time point. For additional analyses at week 12, the last post-baseline observation was carried forward to impute missing data. Comparison of treatment effects was performed by analysis of covariance (ANCOVA), with baseline as a covariate. No adjustments were made for multiple statistical comparisons. ANCOVA results were reported as <italic>P</italic> values (for the test of null hypothesis of no difference between treatments). A 2-sided significance level of 5% was applied to all statistical tests.</p></sec></sec><sec sec-type="results"><title>Results</title><p>For each IPSS symptom, mean baseline values for the silodosin and placebo groups were similar (<xref ref-type="table" rid="t1-oaju-3-001">Table 1</xref>). Mean baseline scores ranged from 2.2 points for straining to 3.6 points for weak stream (<xref ref-type="table" rid="t1-oaju-3-001">Table 1</xref>). For each IPSS symptom, improvement from baseline to week 12 (last observation carried forward) was significantly greater in patients who received silodosin than in those who received placebo (<xref ref-type="table" rid="t2-oaju-3-001">Table 2</xref>). The difference between silodosin-related and placebo-related mean changes from baseline to week 12 (last observation carried forward) was smallest for noctu-ria (0.2 points) and greatest for weak stream (0.6 points) (<xref ref-type="table" rid="t2-oaju-3-001">Table 2</xref>).</p><p>All symptom improvements occurred rapidly. Maximum or close to maximum improvement with silodosin versus placebo was achieved at 0.5 or 1 week (<xref ref-type="fig" rid="f1-oaju-3-001">Figure 1</xref>). For all IPSS symptoms except nocturia, the difference in improvement between silodosin and placebo treatment groups was significant at week 0.5 (observed cases). For nocturia, the difference between treatments was significant at week 1 (<xref ref-type="table" rid="t2-oaju-3-001">Table 2</xref>). Symptom improvement with silodosin, expressed as mean percentage reduction in IPSS from baseline to the last observation, ranged from 16.7% for nocturia to 38.2% for straining. Mean symptom improvement was 20.7% and 24.0% for frequency and urgency, respectively, and 25.2% (incomplete emptying) or greater for all obstructive symptoms (<xref ref-type="fig" rid="f2-oaju-3-001">Figure 2</xref>). In contrast, mean symptom improvement with placebo was 10.9% (frequency) or less for irritative symptoms and 16.9% (straining) or less for obstructive symptoms (<xref ref-type="fig" rid="f2-oaju-3-001">Figure 2</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Combined efficacy data from 2 phase III studies with a total of 923 patients demonstrated that once-daily administration of silodosin 8 mg rapidly led to significant improvement in total IPSS and irritative and obstructive symptom subscores<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> and statistically significant improvement (versus placebo) in each of the 7 individual symptoms assessed by the IPSS questionnaire. Except for nocturia, significant improvement was achieved by day 3 or 4 &#x02013; the earliest assessment time point after treatment initiation. Nocturia improved significantly within 1 week of treatment initiation. A previous analysis of patients&#x02019; responses to IPSS Q8, which assesses quality of life related to BPH-associated urinary symptoms, showed that patients who received silodosin generally experienced substantially greater improvement in symptom-related quality of life than those who received placebo.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref></p><p>Given that IPSS subscores for specific symptoms usually are not reported for individual patients, the clinical significance of some of the improvements demonstrated by our analysis is difficult to gauge. Consideration of whether a treatment effect is clinically meaningful is further complicated by the magnitude of positive placebo effect that is often seen when BPH-related LUTS are assessed by questionnaire.<xref ref-type="bibr" rid="b14-oaju-3-001">14</xref> Validation of the original American Urological Association symptom index, which comprises the 7 symptom-related items of the IPSS, showed a variable degree of correlation of each item with the overall score, ranging from 0.54 to 0.83.<xref ref-type="bibr" rid="b13-oaju-3-001">13</xref> The study recorded mean changes in scores following prostatectomy of &#x02212;1.5 (frequency), &#x02212;1.0 (urgency), &#x02212;0.8 (nocturia), &#x02212;1.5 (emptying), &#x02212;1.8 (intermittency), &#x02212;2.4 (weak stream), and &#x02212;1.6 (hesitancy).<xref ref-type="bibr" rid="b13-oaju-3-001">13</xref> In light of these data, the mean changes from baseline to week 12 observed in our study appear to be of clinical significance, particularly those observed for all irritative symptoms (<xref ref-type="table" rid="t2-oaju-3-001">Table 2</xref>). Reductions over 12 weeks in total IPSS were 6.4 points for silodosin and 3.5 points for placebo.<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> This illustrates a highly significant treatment effect of silodosin in terms of statistical significance compared with the placebo effect<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref> and clinically meaningful symptom improvement.<xref ref-type="bibr" rid="b15-oaju-3-001">15</xref> In this post hoc analysis, silodosin on average improved each symptom score (except that for nocturia) by 21% to 38% over the baseline score. These values are substantially higher than the corresponding values for placebo (8.8% to 17%).</p><p>The results of this analysis support previous observations that silodosin is a fast-acting agent that provides significant BPH symptom relief within a few days. The short duration of the study precludes evaluation of the long-term effect (beyond 12 weeks) of silodosin on each of the 7 IPSS symptoms. In a 40-week open-label extension of the 2 placebo-controlled phase III studies of silodosin, patients who had received silodosin in the double-blind studies on average maintained symptom improvement with continued silodosin treatment during the open-label study. In the open-label study, symptoms also were assessed by IPSS total score and IPSS irritative and obstructive subscores.<xref ref-type="bibr" rid="b12-oaju-3-001">12</xref></p></sec><sec><title>Conclusion</title><p>Silodosin, a highly uroselective &#x003b1;-blocker, rapidly and significantly improved all irritative and obstructive BPH-related symptoms assessed by the IPSS questionnaire, and the improvements were maintained over the study period of 12 weeks. Together with the previously reported evidence of its efficacy and excellent cardiovascular tolerability,<xref ref-type="bibr" rid="b11-oaju-3-001">11</xref>,<xref ref-type="bibr" rid="b12-oaju-3-001">12</xref> our results support consideration of silodosin as a valuable new treatment option for patients with symptomatic BPH.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was funded by Watson Laboratories, Inc. Scientific Connexions (Newtown, Pennsylvania) provided medical writing and editorial assistance, with funding from Watson Pharma, Inc.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>All of the authors have financial and/or other relationships with Watson Laboratories. LS Marks also has a financial and/or other relationship with Allergan, American Medical Systems, Astellas, Bayer, Beckman Coulter, Diagnostic Ultrasound, GTX, GlaxoSmithKline, Gen-Probe, Indevus, Light Sciences Oncology, Lilly/ICOS, Merck, Novartis, Onconome, Pfizer, sanofi-aventis, and Solvay, as well as with NIH, CapCURE, Pardee Foundation, and Seder Foundation.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-oaju-3-001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>I</given-names></name><name><surname>Burt</surname><given-names>RP</given-names></name><name><surname>Chapple</surname><given-names>CR</given-names></name></person-group><article-title>Noradrenaline contractions of human prostate mediated by &#x003b1;1A-(&#x003b1;1C-) adrenoceptor subtype</article-title><source>Br J Pharmacol</source><year>1995</year><volume>115</volume><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">8548177</pub-id></element-citation></ref><ref id="b2-oaju-3-001"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwinn</surname><given-names>DA</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>&#x003b1;1-Adrenoceptor subtypes and lower urinary tract symptoms</article-title><source>Int J Urol</source><year>2008</year><volume>15</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">18304211</pub-id></element-citation></ref><ref id="b3-oaju-3-001"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepor</surname><given-names>H</given-names></name></person-group><article-title>Alpha blockers for the treatment of benign prostatic hyperplasia</article-title><source>Rev Urol</source><year>2007</year><volume>9</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">18231614</pub-id></element-citation></ref><ref id="b4-oaju-3-001"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatano</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Tamaki</surname><given-names>M</given-names></name><name><surname>Komeyama</surname><given-names>T</given-names></name><name><surname>Koizumi</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name></person-group><article-title>Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery</article-title><source>Br J Pharmacol</source><year>1994</year><volume>113</volume><fpage>723</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">7858860</pub-id></element-citation></ref><ref id="b5-oaju-3-001"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudner</surname><given-names>XL</given-names></name><name><surname>Berkowitz</surname><given-names>DE</given-names></name><name><surname>Booth</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>2336</fpage><lpage>2343</lpage><pub-id pub-id-type="pmid">10587338</pub-id></element-citation></ref><ref id="b6-oaju-3-001"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Foglar</surname><given-names>R</given-names></name><name><surname>Horie</surname><given-names>K</given-names></name><etal/></person-group><article-title>KMD-3213, a novel, potent, &#x003b1;1A-adrenoceptor-selective antagonist: characterization using recombinant human &#x003b1;1-adrenoceptors and native tissues</article-title><source>Mol Pharmacol</source><year>1995</year><volume>48</volume><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">7651358</pub-id></element-citation></ref><ref id="b7-oaju-3-001"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Okura</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>R</given-names></name></person-group><article-title>In vivo demonstration of &#x003b1;1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues</article-title><source>J Pharmacol Exp Ther</source><year>2001</year><volume>296</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">11123376</pub-id></element-citation></ref><ref id="b8-oaju-3-001"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>S</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Akiyama</surname><given-names>K</given-names></name><name><surname>Muramatsu</surname><given-names>I</given-names></name></person-group><article-title>Tissue selectivity of KMD-3213, an &#x003b1;1-adrenoreceptor antagonist, in human prostate and vasculature</article-title><source>J Urol</source><year>2000</year><volume>164</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">10893647</pub-id></element-citation></ref><ref id="b9-oaju-3-001"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>R</given-names></name><name><surname>Akiyama</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of KMD-3213, an &#x003b1;1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta</article-title><source>Eur J Pharmacol</source><year>1996</year><volume>315</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">8960867</pub-id></element-citation></ref><ref id="b10-oaju-3-001"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>K</given-names></name><name><surname>Hora</surname><given-names>M</given-names></name><name><surname>Tatemichi</surname><given-names>S</given-names></name><etal/></person-group><article-title>KMD-3213, a uroselective and long-acting &#x003b1;1A-adrenoceptor antagonist, tested in a novel rat model</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>291</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10490890</pub-id></element-citation></ref><ref id="b11-oaju-3-001"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>LS</given-names></name><name><surname>Gittelman</surname><given-names>MC</given-names></name><name><surname>Hill</surname><given-names>LA</given-names></name><name><surname>Volinn</surname><given-names>W</given-names></name><name><surname>Hoel</surname><given-names>G</given-names></name></person-group><article-title>Rapid efficacy of the highly selective &#x003b1;1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies</article-title><source>J Urol</source><year>2009</year><volume>181</volume><fpage>2634</fpage><lpage>2640</lpage><pub-id pub-id-type="pmid">19371887</pub-id></element-citation></ref><ref id="b12-oaju-3-001"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>LS</given-names></name><name><surname>Gittelman</surname><given-names>MC</given-names></name><name><surname>Hill</surname><given-names>LA</given-names></name><name><surname>Volinn</surname><given-names>W</given-names></name><name><surname>Hoel</surname><given-names>G</given-names></name></person-group><article-title>Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study</article-title><source>Urology</source><year>2009</year><volume>74</volume><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">19815265</pub-id></element-citation></ref><ref id="b13-oaju-3-001"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Fowler</surname><given-names>FJ</given-names><suffix>Jr</suffix></name><name><surname>O&#x02019;Leary</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association</article-title><source>J Urol</source><year>1992</year><volume>148</volume><fpage>1549</fpage><lpage>1557</lpage><comment>Discussion 1564</comment><pub-id pub-id-type="pmid">1279218</pub-id></element-citation></ref><ref id="b14-oaju-3-001"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madersbacher</surname><given-names>S</given-names></name><name><surname>Marszalek</surname><given-names>M</given-names></name><name><surname>Lackner</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Schatzl</surname><given-names>G</given-names></name></person-group><article-title>The long-term outcome of medical therapy for BPH</article-title><source>Eur Urol</source><year>2007</year><volume>51</volume><fpage>1522</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">17416456</pub-id></element-citation></ref><ref id="b15-oaju-3-001"><label>15</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>American Urological Association</collab></person-group><article-title>Clinical Guidelines: Management of BPH (2003/Updated 2006)</article-title><source>Chapter 1: AUA Guidelines on the Management of Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations</source><ext-link ext-link-type="uri" xlink:href="http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph">http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph</ext-link>Accessed <date-in-citation>2009 May 14</date-in-citation></mixed-citation></ref></ref-list></back><floats-group><fig id="f1-oaju-3-001" position="float"><label>Figure 1</label><caption><p>Change from baseline (week 0) in score for specific International Prostate Symptom Score (IPSS) irritative (<bold>A</bold>) or obstructive (<bold>B</bold>) symptoms. Error bars indicate 95% confidence intervals.</p><p><bold>Abbreviations:</bold> BL, baseline; CFB, change from baseline; LO, last observation after baseline.</p></caption><graphic xlink:href="oaju-3-001Fig1"/></fig><fig id="f2-oaju-3-001" position="float"><label>Figure 2</label><caption><p>Symptom improvement (mean reduction in International Prostate Symptom Scores [IPSS] from baseline to last observation) as a percentage of baseline values.</p></caption><graphic xlink:href="oaju-3-001Fig2"/></fig><table-wrap id="t1-oaju-3-001" position="float"><label>Table 1</label><caption><p>Baseline values for individual symptoms assessed by the IPSS questionnaire</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Baseline, mean (SD)</th><th align="left" valign="top" rowspan="1" colspan="1">Silodosin (n = 466)</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo (n = 457)</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Irritative symptoms</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Frequency (Q2)</td><td align="left" valign="top" rowspan="1" colspan="1">3.5 (1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">3.5 (1.05)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Urgency (Q4)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (1.32)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (1.27)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nocturia (Q7)</td><td align="left" valign="top" rowspan="1" colspan="1">2.8 (1.19)</td><td align="left" valign="top" rowspan="1" colspan="1">2.8 (1.19)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Obstructive symptoms</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Incomplete emptying (Q1)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.27)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Intermittency (Q3)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.25)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Weak stream (Q5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.6 (1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">3.6 (1.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Straining (Q6)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.43)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.37)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-oaju-3-001"><p><bold>Abbreviations:</bold> IPSS, International Prostate Symptom Scores; Q, question; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-oaju-3-001" position="float"><label>Table 2</label><caption><p>Differences in treatment-related IPSS changes from baseline<xref ref-type="table-fn" rid="tfn2-oaju-3-001">a</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">IPSS questions</th><th align="left" valign="top" rowspan="2" colspan="1">Week</th><th colspan="2" align="left" valign="top" rowspan="1">Change from baseline, mean (SD)
<hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Silodosin (n = 466)</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo (n = 457)</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> value<xref ref-type="table-fn" rid="tfn3-oaju-3-001">b</xref></th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Irritative symptoms</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Frequency (Q2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (1.08)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (0.96)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.9 (1.34)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Urgency (Q4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.21)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0075</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (1.36)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.27)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x02003;Nocturia (Q7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.06)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (1.03)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0968</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (1.07)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (1.05)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0091</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0037</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Obstructive symptoms</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Incomplete emptying (Q1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (1.14)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (0.97)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.9 (1.42)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (1.22)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Intermittency (Q3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (1.19)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (1.41)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (1.33)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Weak stream (Q5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (1.29)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (1.03)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (1.41)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (1.21)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Straining (Q6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (1.21)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.9 (1.32)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (1.24)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn2-oaju-3-001"><label>a</label><p>Week 12 (last observation carried forward);</p></fn><fn id="tfn3-oaju-3-001"><label>b</label><p>Silodosin versus placebo.</p></fn><fn id="tfn4-oaju-3-001"><p><bold>Abbreviations:</bold> IPSS, International Prostate Symptom Score; Q, question; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>